Liminatus Pharma shares surge 21.27% premarket after completing $4 million equity offering.

Liminatus Pharma surged 21.27% in premarket trading following the completion of a $4 million public equity offering and the implementation of 180-day lock-up agreements by directors and executive officers. The offering, priced at $0.29 per share, included 8.27 million shares and warrants, generating $3.46 million in net proceeds to fund clinical trials, R&D, and operational expenses. The lock-up agreements, effective from February 17, 2026, restrict insider selling for six months, signaling management’s confidence in post-offering stability and aligning with investor expectations of capital deployment for growth initiatives. The dual announcements—capital.